Drug Trial Radar · NCT03400995
A Study to Evaluate the Pharmacokinetics, Metabolism, and Excretion of AK0529
Last checked: Nov 20, 2026Latest source record: Sep 11, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
7
Actual
Start
Jan 5, 2018
Primary completion
Feb 27, 2018
Study completion Aug 30, 2018
Sponsor
- Lead sponsor
- Shanghai Ark Biopharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jan 17, 2018
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Male only, from 30 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This phase I study is to assess the mass balance recovery after a single oral dose of \[14C\]-AK0529 in healthy male subjects.
Conditions
- Healthy
Interventions
AK0529Drug
A solution containing 300 mg radiolabelled AK0529.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Amount excreted (Ae)Time frame: At approximately 6 weeks
- Percentage of the administered dose (%Ae)Time frame: At approximately 6 weeks
- Cumulative recovery (CumAe)Time frame: At approximately 6 weeks
- Percentage of cumulative recovery of the administered dose (Cum%Ae)Time frame: At approximately 6 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Quotient Clinical
Nottingham, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.